Immunohistochemical Expression of Apoptosis Regulators in Squamous Cell Carcinoma of the Cervix and Their Association with Human Papillomavirus 16/18 Subtypes

Abstract

Background: Human papillomavirus (HPV) infection is an important aetiological factor in squamous cell carcinoma (SCC) of the cervix. Limited studies have been focused on the differences between carcinogenesis of SCCs with and without HPV infection. Aims: The main goal of this study is to determine the expression of some of the apoptotic pathway regulators, including P53, Bax and Bcl2 in SCCs with and without high risk HPV 16/18 infection. Study Design: Cross sectional study. Methods: A total of 42 paraffin-embedded blocks with the histopathological diagnosis of invasive SCC with determined HPV 16/18 status were selected; half of them were HPV positive and the rest were negative. Afterwards, immunohistochemistry stained slides for p53, Bcl2 and Bax were evaluated with H-score, multiplicative and Additive Quick score by two pathologists; in cases of controversy about the results, the mean results were recorded. Results: Mean results and percentage of expression of our three markers were significantly higher in the HPV 16/18 infected group than in uninfected individuals: Respectively, the mean score for Bcl2, Bax and p53 staining according to H-scoring method was 68.5, 234, 106.4 in the HPV 16/18 infected group and 4.5, 218.8, 5.07 in the uninfected group; and the Multiplicative Quick score was 4, 14.6, 8.2 in the HPV 16/18 infected group and 3, 12.3, 3.5 in the uninfected group. Conclusion: High risk HPVs possibly act in favour of apoptotic pathway inactivation. The significant difference in apoptotic pathway between SCCs with and without high risk HPVs suggests a different early carcinogenesis pathway. (Balkan Med J 2014;31:202-7)

Keywords

• Bax, Bcl2, cervix, human papilloma virus, p53, squamous cell carcinoma

References

1. 1. Rosai J. Rosai and Ackerman’s surgical pathology. 10th ed, Vol 2. Edinburgh-New York: Mosby; 2011:1447.
2. 2. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003;13;88:63-73. [CrossRef]
3. 3. Mozzetti S, Ferrandina G, Marone M, D’Ingiullo F, Fruscella E, De Pasqua A, et al. Bcl-2, bax, bcl-x(L) and bcl-x(S) expression in neoplastic and normal cervical tissue. Cancer Detect Prev 2000;24:536-41.
4. 4. Baskaran K, Satish R, Scinthosh V, Govindaraju R, Manoharan Sh, Sethupathy S. Expression pattern of pro- and anti-apoptotic proteins in patients with squamous cell carcinoma of the uterine cervix. Int J Res 2010;4:546-50.
5. 5. Liverani CA , Ciavattini A, Monti E, Puglia D, Mangano S, DI Giuseppe J, et al. High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions. Am J Transl Res 2012;4:452-7.
6. 6. Spitkovsky D, Aengeneyndt F, Braspenning J, von Knebel Doeberitz M. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene 1996;13:1027-35.
7. 7. Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, et al.Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. Virol J 2010;7:201. [CrossRef]
8. 8. Gaia CD, Jancu IV, Socolov D, Botezatu A, Lazaroiu AM, Huica I, et al. The expression of cell cycle regulators in HPV- induced cervical carcinogenesis. Roma Bio Let 2010;15:5376-83.

9. 9. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999;18:2449-58. [CrossRef]
10. 10. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV16 E7 oncoprotein. Genes Dev 1997;11:2090-100. [CrossRef]
11. 11. Stacey SN, Jordan D, Williamson AJ, Brown M, Coote JH, Arrand JR. Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA. J Virol 2000;74:7284-97. [CrossRef]
12. 12. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998;17:2943-54. [CrossRef]
13. 13. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850-5. [CrossRef]
14. 14. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 2002;21:5088-96. [CrossRef]
15. 15. Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6’s induction of epithelial hyperplasia in vivo. J Virol 2003;77:6957-64. [CrossRef]
16. 16. Nguyen MM, Nguyen ML, Caruana G, Bernstein A, Lambert PF, Griep AE. Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol 2003;23:8970-81. [CrossRef]
17. 17. Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K, et al. Life cycle heterogeneity in animal models of human papillomavirusassociated disease. J Virol 2002;76:10401-16. [CrossRef]
18. 18. Grace VM, Shalini JV, lekha TT, Devaraj SN, Devaraj H. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2003;91:51-8. [CrossRef
19. 19. Feng W, Xiao J, Zhang Z, Rosen DG, Brown RE, Liu J, et al. Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. Mod Pathol 2007;20:961-6. [CrossRef]
20. 20. Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, Goovaerts GC, et al. The importance of biological factors (Bcl-2, Bax, p53 PCNA, MI, HPV and angiogenesis), in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001;97:223-30. [CrossRef]
21. 21. Win N, Thu Th, Tun N, Aye Th, Soe S, Nyunt K, et al. p53 expression in carcinoma cervix. Myan Med J 2004;48:38-41.
22. 22. Kokawa K, Shikone T, Otani T, Nakano R. Apoptosis and the expression of Bax and Bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Cancer 1999;85:1799-809. [CrossRef]
23. 23. Sun Yong M, Chen Ying X, Jia Hui Y, Wang Yu W, Xie Qiu H. Expression and significance of PCNA, Ki- 67, p53 and β-HCG in squamous cell carcinoma of the cervix. Jian J China 2009;17:222-23.
24. 24. Giarnieri E, Mancini R, Pisani T,Alderisio M, VecchioneA. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2000;6:3600-6.
25. 25. Singh A, Sharma H, Salhan S, Gupta SD, Bhatla N, Jain SK, et al. Evaluation of expression of apoptosis-related proteins and their correlation with HPV ,telomerase activity, and apoptotic index in cervical cancer. Pathobiology 2004;71:314-22. [CrossRef]
26. 26. Pezeshkpoor F, Jafarian AH, Ghazvini K, Yazdanpanah MJ, Sadeghian A, Esmaili H, et al. An association of human papillomaviruses low risk and high risk subtypes with skin tag. Iran J Basic Med Sci 2012;15:840-4.
27. 27. Sadeghian MH, Ayatollahi H, Keramati MR, Memar B, Jamedar SA, Avval MM, et al. The association of Epstein-Barr virus infection with multiple myeloma. Indian J Pathol Microbiol 2011;54:720-4.
28. 28. Keramati MR, Sadeghian MH, Ayatollahi H. Clinical and laboratory features in adult T-cell leukemia/lymphoma in Khorasan, Iran. Leuk Lymphoma 2010;51:727-9. [CrossRef]
29. 29. Nayereh KG, Khadem G. Preventive and therapeutic vaccines against human papillomaviruses associated cervical cancers. Iran J Basic Med Sci 2012;15:585-601.
30. 30. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med 2010;13:143-6.
31. 31. Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res 2012;18:929-37. [CrossRef]
32. 32. Tavakkol-Afshari J, Brook A, Mousavi SH. Study of cytotoxic and apoptogenic properties of saffron extract in human cancer cell lines. Food Chem Toxicol 2008;46:3443-7. [CrossRef]
33. 33. Cho NH, Lim SY, Kim YT, Kim D, Kim YS, Kim JW. G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value. Gynecol Oncol 2003;90:15-22. [CrossRef]
34. 34. Protrka Z, Arsenijevic S, Dimitrijevic A, Mitrovic S, Stankovic V, Milosavljevic M, Kastratovic T, Djuric J. Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions. Eur J Histochem 2011;55:44-9. [CrossRef]
35. 35. Van de Putte G, Holm R, Lie AK. Markers of apoptosis in stage IB squamous cervical carcinoma. J Clin Pathol 2005;58:590-4. [CrossRef]
36. 36. Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 2010;31:402-10. [CrossRef]
37. 37. Huh WK, Gomez-Navarro J, Arafat WO, Xiang J, Mahasreshti PJ, Alvarez RD, et al. Bax induced apoptosis as novel gene therapy approach for carcinoma of the cervix. Gynecol Oncol 2001;83:370-7. [CrossRef]